Study record · Semaglutide (oral)
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Mean weight change was -13.6% with oral semaglutide versus -2.2% placebo; multiple categorical weight-loss thresholds also favored semaglutide.
Key result
Mean weight change was -13.6% with oral semaglutide versus -2.2% placebo; multiple categorical weight-loss thresholds also favored semaglutide.
Study details
Study designRandomized, double-blind, placebo-controlled trial
PhasePhase III
PopulationAdults with obesity or overweight plus at least one weight-related complication, without diabetes
Sample size307
RouteOral
Regimen / exposureSemaglutide 25 mg once daily plus lifestyle intervention
Duration64-week efficacy endpoint; 71-week trial
ComparatorPlacebo
Primary endpoint / questionPercent body-weight change and >=5% weight loss
Safety resultGI adverse events occurred in 74.0% versus 42.2% with placebo.
Key limitationsFormulation/dose-specific obesity trial; do not transfer results to all oral semaglutide products or strengths.
Registry / identifierPMID 40934115 / NCT05564117